HANGZHOU, CHINA, September 3, 2026 – Doer Biologics Co., Ltd. ("Doer Biologics"), a clinical-stage biopharmaceutical company and a subsidiary of Huadong Medicine, focused on developing innovative biologic therapeutics for metabolic diseases and cancer, today announced that the first subject has been successfully dosed in its Phase Ib study of DR30206, a tri-specific multi-target innovative drug, in combination with standard chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) at Shandong Cancer Hospital.
DR30206 for injection is a Class 1 therapeutic biologic product independently developed by Doer Biologics with global intellectual property rights. DR30206 is an antibody-fusion protein targeting PD-L1, VEGF, and TGF-β. It restores the proliferation of exhausted CD8+ T cells by blocking the PD-1/PD-L1 signaling pathway; and it reduces tumor neovascularization while relieving immunosuppression by specifically binding free VEGF and TGF-β, thereby achieving tumor killing effects.
On June 28, 2023, Doer Biologics received the Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), approving the clinical trial application for DR30206 for injection and granting permission to conduct clinical trials in patients with advanced solid tumors. On April 16, 2025, the first subject was dosed in the Phase Ib trial for NSCLC. On April 3, 2025, Doer Biologics received another Clinical Trial Approval Notice from the NMPA, approving the trial of DR30206 in combination with standard chemotherapy for advanced or metastatic gastrointestinal tumors, and the first subject was dosed in the Phase Ib study for this indication on June 11, 2025. Additionally, on November 20, 2025, the first subject was dosed in the Phase Ib monotherapy expansion cohort for head and neck squamous cell carcinoma. On January 29, 2026, the first subject was dosed in the Phase Ib monotherapy expansion cohort for platinum-resistant ovarian cancer. On February 26, 2026, Doer Biologics received another Clinical Trial Approval Notice from the NMPA, approving the trial of DR30206 in combination with standard chemotherapy for patients with locally advanced or metastatic NSCLC.
Completed nonclinical studies have demonstrated that DR30206 has a clear mechanism of action and exhibits tumor-growth inhibitory activity. This Phase Ib clinical study of DR30206 in combination with standard chemotherapy for locally advanced or metastatic NSCLC plans to enroll patients with both squamous and non-squamous NSCLC.
Dr. Yanshan Huang, Founder and Chief Executive Officer of Doer Biologics, commented: "DR30206 is an innovative tri-specific biologic drug designed, engineered, and developed using Doer Biologics' proprietary SMART-VHHBody and MultipleBody® platform technologies. It exhibits high affinity and excellent specificity for all three targets—PD-L1, VEGF, and TGF-β. Nonclinical studies have shown that DR30206 demonstrates potent antitumor activity across multiple different solid tumor models."
Dr. Yongliang Fang, Chief Operating Officer of Doer Biologics, commented: "We are encouraged by the ongoing progress of the Phase Ib clinical study of DR30206 in combination therapy. The ongoing Phase Ia dose-escalation and Phase Ib expansion trials have shown favorable human tolerability and early efficacy signals in NSCLC. The dosing of the first subject in this Phase Ib combination trial with standard chemotherapy for locally advanced or metastatic NSCLC at Shandong Cancer Hospital represents another important milestone in the clinical development of DR30206. Recent scientific advances both domestically and internationally also highlight the importance of multi-target immunotherapeutic agents for NSCLC treatment. We look forward to DR30206 offering a new treatment option for NSCLC patients in the future."
For more information on the clinical trials of DR30206 in China, please refer to the Drug Clinical Trial Registration and Information Disclosure Platform (Registry numbers: CTR20233502, CTR20251945, CTR20262489).